The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Community Fast Track, 2005Nigrostriatal Dopaminergic Degeneration and Alpha-synuclein Aggregation in Mice with Reduced TrkB Signaling
Parkinson's disease (PD) is characterized by progressive loss of dopaminergic neurons and deposition of cytoplasmic protein aggregates termed Lewy bodies (LB) in a brain structure termed substantia...
-
Community Fast Track, 2005Pathophysiological Role of PINK1 in Rodent Brain
Mutations in the PINK1 gene were recently linked to autosomal recessive parkinsonism. However, to date, very little is known about the role of PINK1 in the brain. Our group has ample expertise with...
-
Community Fast Track, 2005Novel Therapeutic Approaches for Parkinson ’s Disease
Our goal is to develop novel therapeutic agents for the treatment of Parkinson's disease. We will focus on two compounds. One of these blocks the mitochondrial permeability transition (MPT), which is...
-
Community Fast Track, 2005Neoangiogenesis and Blood-Brain Barrier in L-DOPA-induced Dyskinesia
Fluctuations in brain levels of levodopa play a key role in the production of dyskinesia (abnormal involuntary movements) and motor fluctuations in Parkinson's disease. This project explores the...
-
Community Fast Track, 2005A Novel Animal Model to Identify the Contribution of Iron Mismanagement to Neurotoxicity and a-synuclein deposition in Basal Ganglia
Iron in the substantia nigra is an etiological factor in PD. In addition, iron is established as a key determinant in neurotoxin-based models of PD. Iron is critical for cells to interact with oxygen...
-
Community Fast Track, 2005Activation of Nrf2 neuroprotective pathways for Parkinson’s disease
Parkinson's disease is characterized by the progressive loss of specific cells of the brain region called substantia nigra that produce the chemical messenger dopamine. The current mainstay therapy is...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.